Medicure (MCUJF) EBIT Margin (2009 - 2026)

Medicure's EBIT Margin history runs 18 years deep, the most recent figure standing at 20.06% for Q1 2026.

• On a quarterly basis, EBIT Margin rose 3200.0% year-over-year to 20.06% in Q1 2026; TTM through Mar 2026 was 6.0%, a 2190.0% increase from a year earlier, with the FY2025 full-year figure at 23.87%, down 1138.0% from the prior year.
• EBIT Margin grew to 20.06% in Q1 2026 per MCUJF's latest filing, from 0.9% in the prior quarter.
• Across five years, EBIT Margin topped out at 92.89% in Q1 2023 and bottomed at 22.45% in Q3 2024.
• The 5-year median for EBIT Margin is 1.36% (2023), against an average of 9.59%.
• Across the five-year window, EBIT Margin sank 9223 bps in 2024 and soared 3335 bps in 2025, its largest moves.
• Year by year, EBIT Margin stood at 85.73% in 2022, then tumbled by 93 bps to 6.29% in 2023, then tumbled by 235 bps to 8.48% in 2024, then jumped by 111 bps to 0.9% in 2025, then surged by 2125 bps to 20.06% in 2026.
• Per Business Quant, the three latest MCUJF EBIT Margin figures stand at 20.06% (Q1 2026), 0.9% (Q4 2025), and 10.9% (Q3 2025).